ISLET Act
Sponsored By: Representative Norman
Introduced
Summary
Classifies human cadaveric islets used for transplantation as organs. The bill removes these islets from the legal categories of drugs, biologics, and human cells, tissues, or cellular or tissue-based products (HCT/Ps) and points regulatory treatment toward organ-transplant rules.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Treat cadaveric islets as organs
If enacted, the bill would add human cadaveric islets to the statutory list of organs. It would say cadaveric islets are not drugs, biological products, or HCT/Ps. The Secretary of Health and Human Services would have to update related regulations within 1 year and report progress to Congress within 6 months. Those changes would shift which organ-transplant rules apply to islet recovery and allocation and would likely affect access and out-of-pocket costs for people who need islet transplants.
Sponsors & CoSponsors
Sponsor
Norman
SC • R
Cosponsors
Bacon
NE • R
Sponsored 3/19/2026
Mann
KS • R
Sponsored 3/24/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in